Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia are two rare diseases for which there are no effective and long lasting treatments. Preliminary studies on trabectedin, a drug acting as transcriptional regulator, showed significant response on these patients. Since the interest on this drug has increased, characterization of its mechanism of action through pharmacogenomics approaches is one of the aims of pharmacological researches in this field.
La leucemia mielomonocitica giovanile e la leucemia mielomonocitica cronica sono due malattie rare per le quali ancora non esistono trattamenti efficaci e duraturi. Studi preliminari sulla trabectedina, un farmaco che agisce come regolatore della trascrizione, hanno dimostrato una risposta efficace su questi pazienti. Dal momento che l'interesse per tale farmaco è crescente, la caratterizzazione del suo meccanismo d'azione attraverso la farmacogenomica è uno degli obiettivi della ricerca farmacologica in questo campo.
Pharmacogenomics approaches for the characterization of the mechanism of action of trabectedin in a model of juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
MANNARINO, LAURA
2014/2015
Abstract
Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia are two rare diseases for which there are no effective and long lasting treatments. Preliminary studies on trabectedin, a drug acting as transcriptional regulator, showed significant response on these patients. Since the interest on this drug has increased, characterization of its mechanism of action through pharmacogenomics approaches is one of the aims of pharmacological researches in this field.| File | Dimensione | Formato | |
|---|---|---|---|
|
mannarino_laura_tesi.pdf
non accessibile
Descrizione: Testo della tesi
Dimensione
6.46 MB
Formato
Adobe PDF
|
6.46 MB | Adobe PDF | Visualizza/Apri |
I documenti in POLITesi sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/10589/107348